Powered by Rouse

Powered by Rouse, the emerging markets IP firm. www.rouse.com

Tuesday, March 20, 2012

Terms of compulsory licenses granted

Further to the recent decision in India and the post here IP Komodo thought it helpful to compare known compulsory license terms (known from the media reports at least). Any additional information is welcome, to update, add to or correct this.

Country
Date
compound
Patentee
Royalty
Purpose
Term







Indonesia
5.10.04
lamivudine
GSK
0.5% of the net sales price
for government use
Patent expiry 2011
Indonesia
5.10.04
nevirapine
Boehringer Ingelheim
0.5% of the net sales price
for government use
Patent expiry 2012
Thailand
25.1.07
efavirenz
Merck
0.5% of the original cost of the drug
public non-commercial use for importation and local production

Thailand
25.1.07
opinavir/ritonavir
Abbott

public non-commercial use for importation and local production

Thailand
25.1.07
clopidogrelc
Sanofi-Aventis & Bristol-Myers Squibb.

public non-commercial use for importation and local production

India
9.3.12
sorafenib
Bayer
6% of net sales (up to max. price of 8880 Rps/pack)
Manufacture by NATCO only in India.
Patent expiry

No comments:

Post a Comment